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Abstract
Background
Skin and soft tissue infections (SSTI) are a common but preventable cause of morbidity and
mortality among people who inject drugs (PWID). They can be severe, and hospitalisations
of PWID with SSTI are rising. The most common SSTI presentations are abscesses and
cellulitis.
Methods
We used data from Care & Prevent, a cross-sectional community survey of PWID in Lon-
don. We reported the lifetime prevalence of SSTI, severity of infections, key risk factors, and
associated sequelae. Pictorial questions were used to assess SSTI severity.
Results
We recruited 455 PWID. SSTI lifetime prevalence was high: 64% reported an abscess and/
or cellulitis. Over one-third (37%) reported a severe infection, 137 (47%) reported hospitali-
sation. SSTIrisk factors were: aged 35+ years, injecting once or more times a day, subcuta-
neous or intra-muscular injections, and making four or more attempts to achieve an
injection. Those who reported having other health conditions were at higher odds of having
an abscess or cellulitis, with risk tending to increase with number of reported conditions.
Half (46%) employed self-care for their worst SSTI, and 43% waited for ten or more days
before seeking medical care or not seeking medical care at all.
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Conclusions
Abscess and cellulitis are very common among PWID in London. We corroborate findings
indicating SSTIs are associated with risks, e.g. venous access problems, as well as other
co-morbid conditions: septicaemia, endocarditis, DVT, and kidney disease. These co-mor-
bidities may impact SSTIs severity and outcomes. Delayed healthcare seeking potentially
exacerbates infection severity, which in turn increases poorer health outcomes and
complications.
Introduction
Skin and soft tissue infections (SSTI) are a preventable cause of morbidity and mortality
among people who inject drugs (PWID) [1, 2]. In the United Kingdom, SSTI prevalence is ris-
ing [3], with hospitalisations for severe injecting-related infections increasing annually from
2012 [4]. Abscesses and cellulitis are common presentations, treatable with timely primary
care [5]. Delayed care seeking can lead to serious infections such as septicaemia and endocar-
ditis, requiring specialist inpatient intervention [6]. Costs associated with SSTI-related compli-
cations among PWID in the UK are substantial, with a 2012 estimate placing health care
burden to the NHS in the region of £77 million per annum [7]. Studies have also documented
outbreaks of invasive group A streptococcus (iGAS) and invasive Methicillin-Resistant Staphy-
lococcus aureus (iMRSA) among street homeless PWID as well as prisoners and other margin-
alised populations. In the majority of these cases an injection site infection has been present [8,
9]. In a context of barriers to timely medical care access, PWID have been reported to self-
medicate with old or incomplete antibiotic prescriptions [10, 11]. This is a concern, given
potential for antiboitic resistance and vulnerability to MRSA aquistion [12].
A recent systematic review of injecting-related injury and disease found past-month preva-
lence of SSTI among PWID between 6% (UK) and 32% (USA), and lifetime prevalence
between 6% (Australia) and 69% (Ireland) [13]. This variation is likely to relate to factors
including drug type and form (e.g., ‘black tar’ heroin is associated with higher risk of SSTI
than powder heroin), variable harm reduction and healthcare service provision, and drug
preparation and administration practices [14–16]. UK National surveillance data found that
54% of PWID reported symptoms of an SSTI in the past 12 months, but did not capture sever-
ity or sequelae [3]. In this paper we present findings from an in-depth cross-sectional survey
with PWID in London, with a focus on SSTI prevalence, severity, care seeking delay and asso-
ciated health complications.
Methods
Care & Prevent (C&P) is a mixed method project aiming to explore risk factors for, and preva-
lence of, SSTI and associated sequelae among PWID in London. Study rationale and methods
detail have been published [17]. Ethical approvals were obtained from the London Bridge
Research Ethics Committee [17/LO/0872] and the LSHTM Observational Research Ethics
Committee [12021]. All participants provided written consent. Survey participants received a
£10 voucher as reimbursement for their time.
Participants
Participants were eligible for recruitment if they were aged 18 years or older at the time of the
study and had a history of injecting psychoactive drugs. Recruitment was conducted through
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six drug treatment services and through a homeless outreach team visiting homeless hostels
and day centres across London, UK. Participants were informed about the study through a
notice in the service waiting room and through participant information sheets supplied by key-
workers and/or nurses during clinical appointments. Researchers were present at the sites on
specified days to provide further information.
Data generation
Data generation methods comprised: a computer assisted researcher administered SSTI risk
factor questionnaire, urinalysis for proteinuria, and in-depth qualitative interviews. This paper
reports findings from the questionnaire data, generated between October 2017 and March
2019 using Open Data Kit (ODK) software [18]. Data are available upon request.
Measurements
The questionnaire was developed through consultation with a panel of experts and drew on
existing surveys such as the Unlinked Anonymous Monitoring (UAM) Survey, a National sur-
veillance study with PWID conducted annually [17]. Question domains comprised: socio-
demographics; drug use history, injection preparation and administration practices (lifetime
and previous 12 months); reuse and cleaning of injecting equipment (lifetime); experience of
SSTI and other health conditions and care seeking practices (lifetime). Questions pertaining to
SSTI experience were accompanied by pictures of abscesses and/or cellulitis at different stages
(Figs 1 and 2). Still-based images are a reliable method for the assessment of wounds, their
type and severity [19], with evidence that photographs can illicit clinical evaluations equivalent
to those conducted in person [20]. Participants were shown SSTI photographs along with a
Fig 1. From left to right: Mild, moderate, and severe abscess.
https://doi.org/10.1371/journal.pone.0235350.g001
Fig 2. From left to right: Mild, moderate, and severe cellulitis.
https://doi.org/10.1371/journal.pone.0235350.g002
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verbal description of symptoms in order to help correct identification and to aid nomination
of severity. For abscesses and cellulitis, participants were asked if they had experienced either
infection, on how many occasions, bodily location/s and how they rated their worst infection
(mild, moderate, or severe).
SSTI risk factor questions included detail on reuse of injecting equipment, injecting hygiene
practices, primary drugs injected, type and amount of acidifier used to prepare injection solu-
tions, number of injections per day, week or month, body sites injected and number of times
taken to achieve an injection. The latter question was included as it provides a strong indica-
tion of peripheral venous damage–a risk factor for SSTI [16]. Participants were asked about
care seeking practices for SSTI, including duration of time taken from noticing an infection to
seeking medical advice and any SSTI-related hospitalisations. Measures pertaining to care
seeking were informed by prior epidemiological SSTI risk factor and hospitalisation research
[21], which used five or more days as an indicator of health care delay. We incorporated the
five-day measure, also including ten or more days in recognition of the multiple barriers many
PWID face in seeking care. Qualitative interviews provided specificity regarding time taken to
seek care and the contexts which acted to facilitate or delay engagement with medical services.
These findings are published separately [22].
In addition to SSTI and hospitalisation specific questions, participants were asked if they
had received a medical diagnosis for the following health conditions: blood poisoning, arthri-
tis, hepatitis B and C, deep vein thrombosis (DVT), diabetes, kidney disease, necrotising fascii-
tis, human immunodeficiency virus (HIV), chronic obstructive pulmonary disease (COPD),
liver cirrhosis, tuberculosis, bone and/or joint infection, endocarditis, lymphangitis, and
hypertension. These conditions were determined in relation to their potential to confound
findings because they can cause inflammation, and/or affect the functioning of the immune or
circulatory systems. We also asked participants whether they had ever had an invasive bacterial
infection, defined as an infection of the blood, bones, joints, heart, or fascia. These infections
were removed from the final analysis to demonstrate a clearer hypothetical causal pathway
from comorbidities (other than invasive infections) to SSTIs to invasive infections.
Statistical analysis
Descriptive statistics, including means, medians and ranges are presented for the study popula-
tion, and those who reported lifetime history of an abscess and/or cellulitis. All variables in
this study are reported across the participants’ injecting career, unless stated otherwise. Corre-
lations between risk factors and having ever experienced an abscess and/or cellulitis were
assessed using Chi-square tests of independence. Exposure variables associated with the out-
come were assessed using logistic regression models on Stata version 15.1 [23]. Analyses were
performed using logistic regression to assess those at higher risk of having an abscess and/or
cellulitis. All regression models were adjusted using sex, age, and lifetime experience of street
homelessness.
Results
Description of sample population
Four-hundred and fifty-five participants completed the questionnaire (Table 1). Three-quar-
ters (75%) of the participants were men, with an average age of 46 years (IQR = 39–52). Over
three quarters (78%) of the study population had lifetime history of street homelessness. SSTI
prevalence was high, with 64% (95% CI 60–68) reporting lifetime experience of abscess and/or
cellulitis. Of the 249 (55%) who reported at least one abscess, 90 (36%) rated their worst infec-
tion as severe, and 159 (64%) as mild or moderate. Among those who reported at least one
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cellulitis event in their lifetime, 34/155 (22%) rated their worst cellulitis as severe, and 121
(78%) as mild or moderate.
Table 1. Demographic distribution of those with an SSTI of any severity, and those with a severe infection with accompanying Pearson’s chi-square tests of
independence.
Variable Level Total Any SSTI Χ2 p-value
(N = 455) (64%, n = 291)
Sex Male 341 (75.0%) 216 (63.3%) 0.22 0.64
Female 114 (25.0%) 75 (65.8%)
Age <35 years old 58 (12.8%) 28 (48.3%) 20.04 <0.001
35–44 years old 155 (34.1%) 77 (49.7%)
45+ years old 242 (53.2%) 186 (76.9%)
Ever homeless Yes 355 (78.0%) 231 (65.1%) 0.87 0.35
No 100 (22.0%) 60 (60.0%)
Attempts (skin punctures) before achieving injection Once 202 (44.4%) 99 (49.0%) 41.26 <0.001
Twice 82 (18.0%) 56 (68.3%)
Three times 58 (12.8%) 41 (70.7%)
Four or more times 108 (23.7%) 91 (84.3%)
Does not inject in vein 5 (1.1%) 4 (80.0%)
Injecting frequency Weekly (once to six times per week) 138 (30.3%) 31 (22.5%) 19.9 <0.001
Daily or more 317 (69.7%) 260 (82.0%)
Injected in past 12 months Yes 284 (62.4%) 191 (67.3%) 3.56 0.06
No 171 (37.6%) 100 (58.5%)
Main drug injected Heroin 199 (43.7%) 126 (63.3%) 18.60 0.10
Crack 7 (1.5%) 1 (14.3%)
Heroin and crack combined 225 (49.5%) 155 (68.9%)
Methadone 5 (1.1%) 2 (40.0%)
Stimulants (Meth/amphetamines) 15 (3.3%) 6 (33.3%)
Cocaine 2 (0.4%) 1 (50.0%)
Methadrone 1 (0.2%) -
Steroids 1 (0.2%) -
Wash hands prior to injecting Always 134 (29.4%) 81 (60.4%) 1.01 0.60
Sometimes 165 (36.3%) 108 (65.5%)
Never 156 (34.3%) 102 (65.4%)
Wipe injection site prior to injecting Always 207 (45.5%) 126 (60.9%) 1.59 0.45
Sometimes 145 (31.9%) 96 (66.2%)
Never 103 (22.6%) 69 (67.0%)
Reuse needles or syringes Yes 306 (67.3%) 224 (73.2%) 34.66 <0.001
No 149 (32.7%) 67 (45.0%)
Reuse filters Yes 190 (43.7%) 177 (93.2%) 10.52 0.001
No 245 (56.3%) 109 (44.5%)
Comorbidity (diagnosed) No conditions 92 (20.2%) 34 (37.0%) 59.64 <0.001
One condition 143 (31.4%) 81 (56.6%)
Two conditions 94 (20.7%) 71 (75.5%)
Three conditions 66 (14.5%) 52 (78.8%)
Four conditions 34 (7.5%) 30 (88.2%)
Five conditions or more 26 (5.7%) 23 (88.5%)
Χ2 –Pearson’s chi-square test of independence.
p-value–significance at the 0.05 level or less.
https://doi.org/10.1371/journal.pone.0235350.t001
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In univariable analysis, SSTI was associated with older age, number of attempts before suc-
cessful injection into a vein, injecting frequency per week, reusing needles and/or syringes,
and reusing filters. Most participants with an abscess and/or cellulitis were aged 45 or older,
injected once or more a day, required four or more attempts before successful injection into a
vein, and reported reusing needles and/or syringes, and reusing filters.
The relationship between abscesses or cellulitis and invasive infections (e.g. septicaemia
and endocarditis) is summarised in Fig 3. Invasive disease is reported more often among those
reporting severe cellulitis. It is also more frequent among those who have had any abscess than
any cellulitis; however, when any cellulitis is co-reported with an abscess it greatly increases
the likelihood of invasive disease.
The majority of participants employed self-care for their worst SSTI after first noticing
symptoms (n = 135, 46%), followed by seeking medical care (n = 95, 33%). When asked how
long they took to seek medical advice, 60% of participants (121) reported waiting for more
than five days after first noticing symptoms, with more than a third with severe infections wait-
ing for 10 or more days before seeking medical advice or not seeking advice at all (41, 43%). Of
those who reported a bacterial infection, 137/291 (47%) reported an SSTI-related hospitalisa-
tion. The proportion reporting hospitalisation was higher among those with a severe infection,
at 79/107 (74%).
Factors associated with bacterial SSTIs
Lifetime SSTI was associated with being aged 35–44 or 45+ (compared to being aged under
35); injecting once or more a day; sometimes or always reusing needles, syringes, and/or filters;
practicing sub-cutaneous or intra-muscular injection; and taking four or more attempts (skin
punctures) to achieve an injection. Crude and adjusted associations are presented in Table 2.
Compared with those reporting any SSTI, those who reported having had a severe bacterial
Fig 3. Number of participants reporting lifetime abscess and/or cellulitis by severity, and proportions reporting
invasive infections (infections of the blood, bones, joints, heart, and necrotising fasciitis). The box size represents
the number of participants with each combination of abscess/cellulitis severity, and the colour and percentage labels
represent the proportion reporting invasive infections.
https://doi.org/10.1371/journal.pone.0235350.g003
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Table 2. Univariate and bivariate regressions between SSTI bacterial infections and health outcomes. Adjusted models included sex, age, and lifetime experience of
street homelessness.
Ever had bacterial SSTI
(64%, n = 291)
Variable N n(%) Crude Adjusted
OR (95% CI) AOR (95% CI)+
Age
<35 58 28 (48.3%) 1 1
35–44 155 77 (49.7%) 1.92 (1.05–3.51) 2.03 (1.11–3.71)
45+ 242 186 (76.9%) 3.32 (1.90–5.82) 3.68 (2.09–6.50)
Injecting frequency
Less than once a day 138 31 (22.5%) 1 1
Once a day or more 317 260 (82.0%) 1.72 (1.14–2.59) 1.61 (1.05–2.45)
Frequency of needle reuse
Never 149 67 (45.0%) 1 1
Sometimes 255 184 (72.2%) 3.17 (2.08–4.85) 3.44 (2.23–5.30)
Always 51 40 (78.4%) 4.45 (2.12–9.35) 4.04 (1.84–8.89)
Frequency of filter reuse
Never 190 109 (57.4%) 1 1
Sometimes 156 108 (69.2%) 1.67 (1.07–2.61) 1.80 (1.14–2.84)
Always 89 69 (77.5%) 2.56 (1.44–4.56) 2.67 (1.48–4.81)
Wash hands prior to injecting
Yes 299 189 (63.2%) 1 1
No 156 102 (65.4%) 1.10 (0.73–1.65) 1.14 (0.75–1.72)
Wipe injection site prior to injecting
Yes 352 222 (63.1%) 1 1
No 103 69 (67.0%) 1.19 (0.75–1.89) 1.13 (0.70–1.82)
Sub-cutaneous injecting (past 12 months)
No 110 62 (56.4%) 1 1
Yes 176 136 (77.3%) 2.63 (1.57–4.41) 2.55 (1.49–4.35)
Intra-muscular injecting (past 12 months)
No 168 100 (60.0%) 1 1
Yes 118 98 (83.1%) 3.33 (1.88–5.90) 3.10 (1.74–5.52)
Attempts before achieving injection
Once 202 99 (49.0%) 1 1
Twice 82 56 (68.3%) 2.24 (1.30–3.85) 2.14 (1.24–3.66)
Three times 58 41 (70.7%) 2.51 (1.34–4.71) 2.43 (1.32–4.50)
Four or more times 108 91 (84.3%) 5.57 (3.10–10.02) 5.01 (2.75–9.14)
Does not inject in vein 5 4 (80.0%) 4.16 (0.46–37.98) 3.01 (0.30–29.82)
Years injecting main drug
One year or less 57 15 (26.3%) 1 1
2–4 years 70 31 (44.3%) 2.23 (1.05–4.74) 2.49 (1.16–5.34)
5–7 years 50 30 (60.0%) 4.20 (1.85–9.52) 3.95 (1.73–9.02)
8–10 years 55 35 (63.6%) 4.90 (2.19–10.98) 4.84 (2.14–10.92)
11–14 years 31 27 (87.1%) 18.90 (5.66–63.10) 21.84 (6.47–73.73)
15+ years 192 153 (79.7%) 10.98 (5.53–21.84) 10.05 (4.99–20.26)
Comorbidity (diagnosed)
No conditions 92 34 (37.0%) 1 1
One condition 143 81 (56.6%) 2.23 (1.30–3.82) 2.01 (1.16–3.49)
(Continued)
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infection had higher odds of taking ten or more days before seeking medical attention, after
controlling for other SSTI risks [AOR 2.29 (95%CI 1.25–4.20).
Reported comorbidities, other than invasive infections, were common among those who
have experienced a SSTI. Half (48%, n = 220) of the sample reported at least two or more diag-
noses of health conditions. Those who reported having one or multiple health conditions were
at higher odds of co-reporting a SSTI. There was a strong, graded association between the
number of comorbidities and the likelihood of reporting a lifetime SSTI.
Discussion
We used a novel survey technique using photographs of injecting related wounds to measure prev-
alence, type and severity of bacterial SSTIs among a sample of people who inject drugs in London.
Two-thirds of participants reported ever having had an abscess and/or cellulitis, with many priori-
tising self-care and/or taking more than five days to engage with medical care after first noticing
an infection. Nearly half of those experiencing an SSTI reported a serious infection requiring hos-
pitalisation. Invasive bacterial diseases were more commonly reported by those who had also
reported a bacterial SSTI, particularly those with severe localised infections, suggesting that safer
injecting and timely access to wound care in the community may help prevent serious infections.
Our findings on the risks of injection frequency, and non-venous injections e.g. sub-cuta-
neous and intra-muscular, confirm those found by others [20, 24]. A new finding is that of
number of skin punctures per injection is also associated with the risk of SSTI. In our results,
four or more injection attempts prior to successful injection was independently associated
with SSTI and severe SSTI. This may reflect loss of peripheral veins due to venous sclerosis,
which may be due to overuse of acidifiers in injection preparation [25]. As reported in a related
study publication [16], overuse of citric acid or vitamin C in injection preparation can exacer-
bate venous sclerosis. This in turn can require transitions to more risky injection sites (such as
the legs and groin) as well as to increase the likelihood of accidental or purposeful non-venous
injections and associated SSTI risk.
We found a strong graded association between co-morbid health conditions and the risk of
SSTI. This reflects a number of causal pathways, probably acting in both directions. For exam-
ple, disease such as diabetes and HIV may reduce immunity and increase susceptibility to
SSTI. On the other hand, inflammation associated with repeated SSTI may increase the risk of
diseases such as arthritis and kidney disease [26]. In the case of septicaemia and endocarditis,
untreated bacterial infections can spread, through the blood, from the skin infection site caus-
ing serious systemic infection [5]
We highlight an association between severity of infection and the time taken to seek health-
care. We found that most (60%) of our cohort indicated taking five or more days to seek medi-
cal attention after first noticing the symptoms of a bacterial SSTI. This duration has been
Table 2. (Continued)
Ever had bacterial SSTI
(64%, n = 291)
Variable N n(%) Crude Adjusted
OR (95% CI) AOR (95% CI)+
Two conditions 94 71 (75.5%) 5.27 (2.80–9.92) 4.88 (2.57–9.26)
Three conditions 66 52 (78.8%) 6.34 (3.06–13.11) 5.48 (2.62–11.43)
Four conditions 34 30 (88.2%) 12.79 (4.14–39.42) 10.50 (3.39–32.51)
Five conditions or more 26 23 (88.5%) 13.08 (3.65–46.89) 10.02 (2.67–37.57)
https://doi.org/10.1371/journal.pone.0235350.t002
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previously used as a measure of care delay [21] and reflects NHS guidance that care should be
sought immediately on noticing symptoms of a bacterial infection [27, 28]. In adjusted analy-
sis, seeking healthcare 10 or more days after noticing symptoms was independently associated
with ever having a severe SSTI. Notable was the high rates of reported hospitalisation (47%,
n = 137) associated with preventable bacterial infections. Given these findings we posit that
duration of time in seeking healthcare impacts severity of bacterial SSTI. Taking ten or more
days to seek healthcare for an SSTI appears to enhance risk of health complications, such as
septicaemia, and associated inpatient hospital admission.
It is well evidenced that PWID face significant barriers in accessing appropriate healthcare
due to stigma and discrimination from healthcare professionals as well as structural difficulties
in accessing and attending medical appointments [29–31]. Qualitative participant data,
reported elsewhere [22] illustrate that delays in seeking medical care are informed by a com-
plex interplay of social structural issues, including limited time due to money generation
demands; limited hope and expectation of adequate care; fear of opiate withdrawal in the hos-
pital system; and normalised pain in a context of pervasive everyday violence. We emphasise
therefore, the resilience demonstrated when seeking care in constrained circumstances and
the need for structural, rather than purely educational, interventions in capacitating change
[22]. Nearly half (46%) of participants with an SSTI reported undertaking self-care as the first
response to their worst infection. Self-care for bacterial infections is generally not recom-
mended, with some practices (such as self-lancing of abscesses) potentially acting to exacerbate
infection. In a context of barriers to health care, self-care will continue to be the preferred
option for many. Support and resourcing to enable PWID to care for infections (such as
wound care training and dressings) can help facilitate safer practices but also trust and engage-
ment with providers, enhancing healthcare access opportunity.
The proportion of participants reporting a lifetime SSTI in our results (64%) is at the high
end of a range reported in a recent systematic review [13]. This may be related to risk factors
in our sample, such as homelessness or the age of participants, or the method we used, which
included photos to help participants identify infections. 30% of participants reported being
hospitalised for an SSTI at some point in their life. In a recent cohort study of PWID in opiate
substitution treatment in South London, 24% of participants were hospitalised at least once for
a bacterial infection over an average of eight years’ follow-up [32]. These broadly similar values
suggest that similar populations were captured by these two research methods, and also show
that the majority of SSTI are treated outside of hospital.
Strengths and weaknesses
This study captured a wide range of injecting-related risk factors and measured the severity of
infections, which to our knowledge has not been measured in previous studies. The survey
method allowed us to study detailed aspects of participants’ risk environment. The cross-sec-
tional design meant that we were not able to establish a temporal relationship between bacte-
rial SSTIs and these injecting risk factors, or report incidence. This contrasts with longitudinal
studies using healthcare records, which provide more precise estimates of incidence but often
lack detailed risk factor information [32] Self-reported health conditions reported are suscepti-
ble to problems with recall and awareness of diseases, such as kidney disease, where partici-
pants may have been informed of a urinary tract infection but misconstrued this as kidney
disease, and/or may not be aware if the disease is acute or chronic, particularly if they are not
currently engaging with healthcare services.
This study is of importance due to its use of photographs to elicit SSTI recall, which contex-
tualises and increases our understanding of risk factors. The validity of the approach of still
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based images for self-report of SSTI severity is not known. The images were chosen in consul-
tation with skin infection specialists, but have not been validated or compared to a gold stan-
dard (such as clinician evaluation). Despite this, there is plausible predictive validity in the
sense that those with more severe local infections (abscesses and cellulitis) had higher preva-
lence of invasive infections. Clinical diagnosis was not possible in this study as recruitment
was opportunistic and access to skin infection specialist clinicians was not available.
Recruitment through community rather than hospital settings captures a more thorough
assessment of prevalence by engaging those who have restricted access to hospitals and ser-
vices. Analysis has demonstrated that C&P sample is comparable to those of PWID participat-
ing in the larger National UAM surveillance survey [32]. We have some confidence, therefore,
that findings reported in this paper are generalisable to the broader population of PWID in the
UK [33]
Conclusion
We found high lifetime prevalence of SSTI among PWID in London, with severity and health
complications potentially exacerbated by delayed medical care seeking. Interventions to reduce
SSTI prevalence, severity and sequalae need to attend both to injection practice risk factors but
also the social structural barriers faced by PWID in accessing timely health care.
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